India, July 27 -- InnoCare Pharma (INCPF) announced that its novel TYK2 inhibitor, Fadeucravacitinib, achieved the primary endpoint in a registrational Phase III trial in patients with moderate-to-severe plaque psoriasis.
Psoriasis is a chronic, immune-mediated skin disease marked by red, scaly plaques and systemic inflammation, affecting millions worldwide and significantly impacting quality of life. Existing therapies often leave gaps in treatment, creating demand for new oral options.
Fadeucravacitinib is a potent and selective TYK2 allosteric inhibitor that blocks signaling pathways of inflammatory cytokines such as IL-23, IL-12, type 1 IFN, thereby targeting autoimmune and inflammatory processes. Beyond psoriasis, InnCcare is explori...